Ainos Inc
AIMD
Company Profile
Business description
Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.
Contact
8880 Rio San Diego Drive
Suite 800
San DiegoCA92108
USAT: +1 858 869-2986
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2024
Employees
46
Stocks News & Analysis
stocks
Why we’ve downgraded this ASX software player
Morningstar lowers our fair value estimate for Megaport by 16% after mispricing leads to a downgrade in capital allocation rating.
stocks
The market hates this compelling ASX income play
Santos continues to trade at a valuation that implies no growth in the years ahead. Our analyst Mark Taylor thinks that is misguided.
stocks
Lessons from the top performing ASX share
Chasing performance can lead to poor results but investors can still learn from top performers.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,728.50 | 26.20 | -0.30% |
| CAC 40 | 7,281.32 | 25.90 | 0.36% |
| DAX 40 | 20,159.17 | 142.42 | 0.71% |
| Dow JONES (US) | 44,705.53 | 76.47 | -0.17% |
| FTSE 100 | 8,340.47 | 18.94 | -0.23% |
| HKSE | 19,742.46 | 3.86 | -0.02% |
| NASDAQ | 19,480.91 | 76.96 | 0.40% |
| Nikkei 225 | 39,276.39 | 27.53 | 0.07% |
| NZX 50 Index | 12,896.67 | 196.51 | -1.50% |
| S&P 500 | 6,049.88 | 2.73 | 0.05% |
| S&P/ASX 200 | 8,462.60 | 32.60 | -0.38% |
| SSE Composite Index | 3,364.65 | 14.16 | -0.42% |